Skip to content

safety and effects on motor function in adult spinal muscular atrophy type 2 and 3

View source

Similar papers

Open access Oct 2026

Real-world 12-month outcomes of risdiplam in spinal muscular atrophy types 2 and 3

Background: Spinal muscular atrophy is a progressive genetic neuromuscular disorder characterized by degeneration of lower motor neurons and progressive muscle weakness. Risdiplam, an oral survival motor neuron 2 splicing modifier, has demonstrated efficacy in clinical trials; however, real-world data in older and chro...

Eric Dupont, C. Camelo, R. Mendonça et al. · 0 citations
Oct 2026

The Efficacy of Risdiplam in 7 Patients Previously Treated With Nusinersen for Spinal Muscular Atrophy

The disease-modifying therapies (DMTs) for spinal muscular atrophy (SMA) produced impressive improvements in motor function and survival in clinical trials. However, there are limited real-world data regarding combination or sequential treatment with DMTs. We report the clinical outcomes of risdiplam in 7 SMA patients...

Kenji Inoue, Masato Kusumoto, Mariko Ishihara et al. · 0 citations
Open access Sep 2026

Effectiveness and safety of risdiplam in Chinese adolescents and adults with spinal muscular atrophy: a prospective real-world study

Evidence for the efficacy of risdiplam in adolescents and adults with 5q spinal muscular atrophy (SMA) has been demonstrated in clinical trials, but its sustained effectiveness and safety in real-world settings, particularly in Chinese adults, are still limited. We evaluated the effectiveness and safety of risdip...

Han-Ning Su, Bin Wang, Cong-Lian Tian et al. · 0 citations
Oct 2026

Long-term real-world outcomes of nusinersen treatment in patients with spinal muscular atrophy types I-III.

BACKGROUND Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mutations or deletions in the survival motor neuron 1 (SMN) gene, with disease severity influenced by SMN2 copy number. Nusinersen, an antisense oligonucleotide therapy, has emerged as an effective treatment option. This...

Gulshan Aliyeva, Sezan Mergen Kilic, Z. Yapıcı et al. · 0 citations
Open access Oct 2026

An analysis of NIV use among patients with spinal muscular atrophy and amyotrophic lateral sclerosis included in the RARAS project between 2018 and 2024

Background: Neuromuscular diseases, such as Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy, encompass a diverse group of conditions that affect the motor unit, resulting in muscle weakness, atrophy, and respiratory compromise. These diseases often present a progressive course, leading to significant challeng...

J. Ferreira · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.